![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » SANGAMO REPORTS SB-509 TRIAL DATA
SANGAMO REPORTS SB-509 TRIAL DATA
April 7, 2006
Sangamo BioSciences has announced that a Phase I human clinical trial of SB-509 or ZFP Therapeutic for the treatment of diabetic neuropathy appears to be safe and well-tolerated.
The SB-509 is an injectable formulation of plasmid DNA that encodes a zinc finger DNA binding protein transcriptase factor. The dose-escalation study results were presented recently at the 58th Annual Meeting of the American Academy of Neurology in San Diego.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct